ASTRAZENAstrazeneca Pharma India Ltd.
AstraZeneca Pharma India: Delhi High Court directs no coercive steps by NPPA
- Order win
- pharmaceuticals
Reviewed byRachit TripathiBlacklitt Research
AstraZeneca Pharma India (NSE: ASTRAZEN) reported that the Hon'ble High Court of Delhi has directed that no coercive steps be taken by the National Pharmaceutical Pricing Authority (NPPA) in its alleged overcharging matter until the next hearing on 11 Jan 2027, it said in a filing on 02 Nov 2026. The order, dated 29 Oct 2026, covers an amount of ₹151.20 crore, approximately.
Key highlights
- Order dated: 29 Oct 2026
- Received by the company: 30 Oct 2026
- Next hearing: 11 Jan 2027
- Amount covered by the order: ₹151.20 crore, approximately
- Alleged overcharging period: May 2016 to November 2025
The order in numbers
| Item | Detail |
|---|---|
| Authority | Hon'ble High Court of Delhi |
| Order dated | 29 Oct 2026 |
| Date of receipt of the order | 30 Oct 2026 |
| Matter | NPPA notice alleging overcharging for Symbicort Turbuhaler 160/4.5 (Inhaler) under DPCO, 2013 |
| Alleged overcharging period | May 2016 to November 2025 |
| Amount covered | ₹151,19,66,035 approximately (₹151.20 crore), comprising alleged overcharged amount and interest up to 30 Oct 2026 |
| Next hearing | 11 Jan 2027 |
What the order directs
The Hon'ble High Court of Delhi has directed that no coercive steps be taken by NPPA in this matter until the next date of hearing, listed on 11 Jan 2027. Annexure A gives the date of receipt of the order as 30 Oct 2026.
The order directs that NPPA cannot take coercive steps till the next hearing date to recover ₹151,19,66,035 approximately. That sum is made up of the alleged overcharged amount and interest up to 30 Oct 2026.
The NPPA notice and the company's challenge
The filing updates the company's communication dated 30 Jul 2026 about a notice received on 29 Jul 2026 from NPPA. Further to a show cause notice dated 11 Sep 2025, the company received that notice and a subsequent reminder.
The notice alleges overcharging in connection with Symbicort Turbuhaler 160/4.5 (Inhaler) for May 2016 to November 2025 under the Drugs (Prices Control) Order, 2013. The company challenged the demand before the Hon'ble High Court of Delhi.
Next steps in the case for AstraZeneca Pharma India's shareholders
The amount the order refers to is ₹151.20 crore, approximately. The filing does not give an outcome for the company's challenge or for the hearing on 11 Jan 2027, so the next dated step is that hearing.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
